Astrazeneca plc EBIT

Astrazeneca plc (AZN) currently reports a EBIT of $14B as of December 2025. That compares with $10B in the prior-year period — up 34.1% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Astrazeneca plc's EBIT history and peer comparisons.

Astrazeneca plc's EBIT increased from $10B to $14B — a 34.1% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Astrazeneca plc's EBIT of $14B is lower than the Healthcare sector average of $22B. That is roughly 37.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Astrazeneca plc reported $14B in EBIT as of December 2025. That compares with $10B in the prior-year period — up 34.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $14B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Astrazeneca plc, and consider following AZN for alerts when major investors trade the stock.